OncoSynergy Treats First Patient in Clinical Trial of Recurrent Glioblastoma

OncoSynergy, Inc. launched the company’s First-in-Human Phase 1 clinical trial evaluating a treatment of recurrent glioblastoma. Today they announced the first patient has been treated in this trial using OS2966, a first-in-class immunotherapy, and the first ever anti-CD29 (beta 1 integrin) therapeutic to reach human trials. 

“After a decade developing and demonstrating the pre-clinical potential of OS2966 in the most difficult to treat cancers, we are thrilled to have treated our first patient in a study specifically designed to overcome these challenges.”

Anne-Marie Carbonell, MD | OncoSynergy Co-Founder and Chief Executive Officer

Learn more about OS2966 and this innovative trial here.

Share this post

Get the Latest from Brains for the Cure

Add your address to our mailing list to get monthly updates about progress in the fight against brain tumors, as well as new community opportunities.

Brains for the Cure is a program of the Head for the Cure Foundation, which is powered by the generous support of donors. Learn more about how you can join the fight.